Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 303

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

Balsat, Marie, Renneville, Aline, Thomas, Xavier, de Botton, Stéphane, Caillot, Denis, Marceau, Alice, Lemasle, Emilie, Marolleau, Jean-Pierre, Nibourel, Olivier, Berthon, Céline, Raffoux, Emmanuel, Pigneux, Arnaud, Rodriguez, Céline, Vey, Norbert, Cayuela, Jean-Michel, Hayette, Sandrine, Braun, Thorsten, Coudé, Marie Magdeleine, Terre, Christine, Celli-Lebras, Karine, Dombret, Hervé, Preudhomme, Claude, Boissel, Nicolas · 2017 · Journal of Clinical Oncology

Abstract

Purpose: This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed the question of whether NPM1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit. Patients and Methods: Among 229 patients with NPM1m who were treated in the Acute Leukemia French Association 0702 (ALFA-0702) trial, MRD evaluation was available in 152 patients in first remission. Patients with nonfavorable AML according to the European LeukemiaNet (ELN) classification were eligible for ASCT in first remission. Results: After induction therapy, patients who did not achieve a 4-log reduction in NPM1m peripheral blood-MRD (PB-MRD) had a higher cumulative incidence of relapse (subhazard ratio [SHR], 5.83; P < .001) and a shorter overall survival (OS; hazard ratio [HR], 10.99; P < .001). In multivariable analysis, an abnormal karyotype, the presence of FLT3-internal tandem duplication (ITD), and a < 4-log reduction in PB-MRD were significantly associated with a higher relapse incidence and shorter OS. In the subset of patients with FLT3-ITD, only age, white blood cell count, and < 4-log reduction in PB-MRD, but not FLT3-ITD allelic ratio, remained of significant prognostic value. In these patients with nonfavorable AML according to European LeukemiaNet, disease-free survival and OS were significantly improved by ASCT in those with a < 4-log reduction in PB-MRD. This benefit was not observed in those with a > 4-log reduction in PB-MRD, with a significant interaction between ASCT effect and PB-MRD response ( P = .024 and .027 for disease-free survival and OS, respectively). Conclusion: Our study supports the strong prognostic significance of early NPM1m PB-MRD, independent of the cytogenetic and molecular context. Moreover, NPM1m PB-MRD may be used as a predictive factor for ASCT indication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.67.1875

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 303

Metadata

Authors
Balsat, M., Renneville, A., Thomas, X., de Botton, S., Caillot, D., Marceau, A., Lemasle, E., Marolleau, J.-P., Nibourel, O., Berthon, C., Raffoux, E., Pigneux, A., Rodriguez, C., Vey, N., Cayuela, J.-M., Hayette, S., Braun, T., Coudé, M. M., Terre, C., Celli-Lebras, K., Dombret, H., Preudhomme, C., & Boissel, N.
Venue
Journal of Clinical Oncology
Published
2017-01-10
Volume
35
Issue
2
Pages
185-193
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2558761368
Cited by
303
References
34
FWCI
22.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. https://app.cochat.ai/papers/10.1200/jco.2016.67.1875
The paper
Balsat, M., Renneville, A., Thomas, X., de Botton, S., Caillot, D., Marceau, A., Lemasle, E., Marolleau, J.-P., Nibourel, O., Berthon, C., Raffoux, E., Pigneux, A., Rodriguez, C., Vey, N., Cayuela, J.-M., Hayette, S., Braun, T., Coudé, M. M., Terre, C., . . . Boissel, N. (2017). Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.67.1875

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.